Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva UK turns to OTCs

This article was originally published in The Tan Sheet

Executive Summary

Teva UK Ltd. plans to launch beginning this fall more than 20 nonprescription drugs, including analgesics, gastrointestinals and allergy relief products. The branch of Teva Pharmaceutical Industries said Sept. 2 the drugs will be sold through general sales or pharmacy class. "Our generics portfolio is already the widest of any other U.K. generics supplier, and branching out into OTCs seems like the next logical step," said Kim Innes, Teva's commercial director. In the U.S., the firm remains largely on the OTC sidelines and recently licensed to Perrigo its rights to private-label versions of Sanofi-Aventis' Allegra once it switches OTC (1"The Tan Sheet" July 5, 2010)

You may also be interested in...



Perrigo Gains Pole Position In Private-Label Allegra Race

Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Topics

UsernamePublicRestriction

Register

PS104479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel